Background: Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-b (Ab) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer 
Introduction
Amyloid-b protein (Ab) deposition is one of the hallmarks of Alzheimer's disease (AD) [1, 2] . The in vivo detection of amyloid pathology in the human brain has become feasible by the use of [ 11 C]-and [ 18 F]-labeled amyloid binding ligands and positron emission tomography (PET) [3] [4] [5] [6] . In vitro-labeling experiments with the [ 11 C]-labeled amyloid tracer Pittsburg compound B (PIB) disclose plaques on histopathologic slides [7] . Autopsies performed on AD subjects that received amyloid PET before death have shown that areas with a high plaque density showed ligand retention with amyloid PET [8] [9] [10] .
Neuropathologically, the deposition of Ab plaques starts in the neocortex and then expands hierarchically into further brain regions [11] . In the second phase, allocortical plaques occur, whereas in phase 3, additional plaques are found in the basal ganglia and in the diencephalon, in phase 4 in the midbrain and the medulla oblongata, and in the fifth and final phase also in the cerebellum and the pons. These phases of Ab deposition are associated with the parallel development of neurofibrillary tangle (NFT) pathology in the course of preclinical and symptomatic AD. Ab phases 4 and 5 are almost always associated with symptomatic AD [11] . The current guidelines of the National Institute of Aging and the Alzheimer Association (NIA-AA) for the neuropathologic diagnosis of AD recommend the assessment of the Ab phases in concert with the Braak stages for NFT pathology (Braak-NFT stage) and the Consortium to establish a Registry for AD (CERAD) score for the assessment of the frequency of neuritic plaques [12] . According to these guidelines, Ab deposition in the brain indicates the presence of AD pathology regardless of cognitive deficits [12] . Because clinical AD by definition is restricted to demented individuals [13] , the diagnosis of preclinical AD (pre-AD) has been introduced for nondemented cases with positive AD biomarkers [14] . Histopathologically, detectable AD pathology in nondemented cases may, therefore, be classified as pathologically defined pre-AD (p-pre-AD) cases [15, 16] .
Until now, it was not clear whether amyloid PET uptake mirrors the hierarchical pattern of Ab plaque deposition, and if so, which phases of Ab pathology might be detectable with amyloid PET imaging techniques, or how accurate amyloid PET might be for the differential diagnosis between autopsy proven AD, p-pre-AD, non-AD dementias, such as vascular dementia, Lewy body disease (LBD) or frontotemporal lobar degeneration (FTLD), and nondemented non-AD cases. [ 18 F]flutemetamol is structurally similar to PIB [17] and has recently been validated for the detection of amyloid plaques [10] . We compared [ 18 F]flutemetamol amyloid PET with the amyloid plaque phase, neuritic plaque density, and associated NFT pathology in 68 autopsy cases enrolled in the [ 18 F] flutemetamol amyloid PET imaging end-of-life study (GE067-007).
Material and methods

Subjects
The subject cohort of 68 cases was included in the efficacy analysis of the GE-067-007 Phase 3 end-of-life clinical trial and autopsied after death (Table 1) . Dementia, defined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, was noted as present or absent. This was a phase 3, multicenter PET study of [ 18 F]flutemetamol injection for detecting brain Ab (ClinicalTrials.gov identifier NCT01165554). Local institutional review boards or ethics committees approved the study protocol before initiation. All subjects or their legal representatives gave prior written informed consent/assent. Consecutive eligible subjects were 55 years of age, terminally ill with a life expectancy ,1 year, and with general health adequate to undergo study procedures. Patients died of natural causes and serious adverse events were not attributable to [ 18 F]flutemetamol injection [10] . Subjects were ineligible if they were pregnant/lactating, had known/suspected structural brain abnormalities, contraindication(s) for PET, known/suspected hypersensitivity/allergy to [ 18 F]flutemetamol injection (or any component), or had participated in any clinical study using an investigational product within 30 days of signing consent. The scan-death intervals ranged between 0 and 397 days (mean 104 days; median 78 days).
Neuropathology assessments
Brain material received at autopsy and previously used for diagnostic purposes supporting the GE067-007 phase 3 clinical trial was examined. All brains were formalin fixed. The brains were cut in coronal slices and screened macroscopically for the presence of infarcts, hemorrhages, tumors, and inflammatory lesions. For histopathologic analysis and for assessing the amounts of AD-related amyloid plaques, NFTs, and neuritic plaques, we examined paraffin-embedded tissue including parts of the frontal, parietal, temporal, occipital cortex, and entorhinal cortex, the hippocampal formation at the level of the lateral geniculate body, basal ganglia, thalamus, amygdala, midbrain, pons, medulla oblongata, and cerebellum. Paraffin sections of 5 mm thickness from all blocks were stained with hematoxylin & eosin (H&E) and anti-Ab antibodies (1:100, formic acid and heat pretreatment; antiAb; 4G8, SIG-39220; Covance, USA). For neuropathologic diagnosis, sections were stained with the Bielschowsky silver method and immunohistochemical methods for abnormal phosphorylated tau protein (anti-human PHF-tau monoclonal antibody; AT8, prod. no. MN1020, 1:40; Thermo Scientific, UK), a-synuclein (anti-a-synuclein monoclonal antibody; prod. no. NCL-L-ASYN, lot no. 6005209, 1:40; Leica Microsystems, UK), and ubiquitin (anti-ubiquitin polyclonal antibody; prod no. Z0458, 1:400; DakoCytomation, UK). Primary antibodies were detected with biotinylated secondary antibodies (E0354, DakoCytomation) and visualized with the DABMap Kit (Ventana, USA). The phase of Ab plaque pathology (Ab phase) was assessed after screening the Ab-stained sections for plaque distribution according to previously published protocols [11, 18] . The neuropathologic diagnosis of AD pathology was performed as recommended (Table 2 ) [12] . Ab plaques loads were determined in 32 cases as shown in Supplmentary Fig. 3 .
Additional vascular changes were assessed in H&E-stained sections. LBD and multiple system atrophy-related changes were determined using a-synuclein immunohistochemistry. Other tauopathies (FTLD-tau) were diagnosed on the basis of antiabnormal tau protein-stained sections. Ubiquitin-stained sections were used to identify other types of FTLD or motor neuron disease. [11, 12, 35, 36] . Scan-death interval in days. Abbreviations: NFT, neurofibrillary tangle; AD, Alzheimer's disease; PART, primary age-related tauopathy; p-pre-AD, pathologically defined pre-AD. NOTE. A: Determination matrix for the NIA-AA Degree of AD pathology regardless of the clinical status as previously published [12] . Ab phase, Braak-NFT stage and CERAD score for neuritic plaques are required to determine the NIA-AA degree of AD pathology [11, 35, 36] .
B: Subclassification of p-preAD, symptomatic AD, symptomatic AD with non-AD dementia (i.e. mixed dementia), non-AD dementia, definite PART and definite NTF-predominant dementia with respect of the clinical status [13, 14, 16, 19, 37, 38] .
There may be overlap between p-pre-AD and PART if one does not restrict to definite PART without any Ab pathology as done here. NFT-predominant dementia has been included in PART but an alternative classification for FTLD terms demented cases with this type of pathology NFT-predominant dementia [19, 37] . To avoid confusion, we used the term NFT-predominant dementia for the demented "PART" cases. 
Clinicopathologic classification of cases
Demented cases with at least intermediate NIA-AA degrees of AD pathology [12] were considered as symptomatic AD cases; nondemented individuals with AD pathology were referred to as p-pre-AD cases as previously suggested [15, 16] (Table 2) . Nondemented cases without AD pathology were classified as non-AD controls. Non-AD controls included cases with NFT pathology in the medial temporal lobe that recently has been termed primary age-related tauopathy [19] (Table 2) . Patients with non-AD dementia encompassed demented patients with vascular dementia, LBD, and FTLD-tau (argyrophilic grain disease, NFTpredominant dementia, Pick's disease) that did not exhibit intermediate or high degrees of AD pathology indicating that AD pathology was presumably not responsible for dementia. Cases with intermediate or high degrees of AD pathology and apparent lesions of a second dementia-related disorder were classified as a subgroup of AD cases: AD 1 non-AD dementia (identical with mixed dementia; Table 2 ).
[ 18 F]flutemetamol PET image assessments
Amyloid PET imaging was performed at 12 different imaging sites (Supplementary Methods). Before PET imaging, subjects underwent head computed tomography (CT) or magnetic resonance imaging, unless prior images (obtained within 12 months) were available. [ 18 F]flutemetamol injection was administered intravenously at a dose of 185 or 370 MBq of radioactivity at physician discretion (Supplementary Methods). PET images were acquired in 2-minute frames on PET/CT cameras, beginning approximately 90 minutes after injection. Five frames were summed to give a 10-minute scan, which was attenuation corrected using CT data. Equipment used to capture images varied across the 12 imaging sites (Supplementary Methods). Most images were reconstructed iteratively to form 128 ! 128 axial slices, and a Gaussian post-reconstruction smoothing filter was applied to some. The images were evaluated over all as either positive or negative for amyloid by five independent readers blinded to all clinical, demographic, and pathology information. The readers were experienced nuclear medicine physicians or radiologists scoring PET images with knowledge of the respective CT scans. The results reported here are using the majority read for global classification of the GE067-007 images from a reread study (GE-067-021) after automated reader training ( Supplementary Fig. 1, Supplementary Methods) .
The [ 18 F]flutemetamol standard uptake values (SUVs) were measured for five volumes of interest (VOIs) restricted to gray matter and adjusted for atrophy manually, covering the anterior cingulate, the prefrontal cortex, the lateral temporal cortex, the parietal cortex, and one VOI covering both posterior cingulate and precuneus (Supplementary Fig. 2 ). Frame-to-frame motion correction was performed on the dynamic data before quantitative SUV measurements and standard uptake value ratio (SUVR) calculations were made. As reference for cerebellum SUV (SUVR CER ), the cerebellar gray matter SUV was used. To exclude bias by using the cerebellar gray matter as reference, we also obtained SUV for the pons as a reference. SUVRs were calculated as a ratio of cortical region SUV to either the SUVR CER reference or pons SUV reference (SUVR PONS ). A global cortical average (composite SUVR) was calculated averaging the cortical SUVRs. Image processing and VOI analysis were performed using voyager 4 (GE Healthcare, Uppsala, Sweden).
Statistical analysis
Logistic regression analysis, analysis of variance (AN-OVA) and Fisher's exact test were calculated using SPSS 21 statistical software (IBM, Armonk, NY, USA) (Supplementary Methods).
Results
[ 18 F]flutemetamol amyloid PET: Association with Ab-phases
Most (89%) Ab phase 4 and all Ab phase 5 cases exhibited a positive amyloid PET signal, whereas all Ab phase 0, 1, and 2 cases showed a negative PET. Only 33.3% of the Ab phase 3 cases exhibited a positive amyloid PET (Fig. 1 , Table 1 ). This finding was confirmed by measuring Ab plaque loads in 32 of our cases providing a threshold of an Ab plaque load of 5% for [ 18 positivity ( Supplementary Fig. 3 ). Likewise, high Braak-NFT stages and high CERAD neuritic plaques scores as well as high and intermediate NIA-AA degrees of AD pathology were observed in cases with positive PET uptake, whereas cases with a negative amyloid PET exhibited either no or only low degrees of NFT, neuritic plaque pathology as well as low NIA-AA degrees AD pathology or no AD pathology (Fig. 1, Table 1 ). Two cases with NFT-predominant dementia with Braak-NFT stages IV and V showed a negative amyloid PET. Higher densities of neuritic plaques (moderate or frequent) were commonly found in AD cases with a positive amyloid PET although 13 cases with a sparse to moderate neuritic plaque density had negative amyloid PET scans (Table 1) .
In a logistic regression model controlled for age, sex, and scan-death interval Ab phases had a significant influence on the amyloid PET pattern, whereas NFT stages did not show a significant effect on the amyloid PET pattern (Ab phases: P 5 .006, odds ratio [OR]: 12.98, 95% confidence interval [CI]: 2.065-81.583; Braak-NFT stages: P 5 .092). The CE-RAD score for neuritic plaque density was not integrated in this model because of collinearity with the Ab plaque phase. A significant association between the amyloid PET pattern, on the one hand, the Braak-NFT stage and the CERAD neuritic plaque density score, on the other, was observed in separate models without Ab-phase (Braak-NFT stages: P , .001, OR: 3.275, 95% CI: 1.886-5.687; CERAD score: P , .001, OR: 21.023, 95% CI: 4.026-109.772). These results were expected from previously published data examining the associations between NFT pathology and neuritic and Ab plaque pathology [15, 20] .
In agreement with the dichotomous [ 18 F]flutemetamol PET assessment as negative or positive, cortical composite SUVR CER did not show differences among individual Ab phase 0-2 subjects ( Fig. 2 ; SUVR CER ,1.6 except two phase 1 cases: 1.67, 1.72). Phase 3 subjects rated as positive had SUVR CER levels between 1.66 and 1.87. Cases with negative PET assessment had SUVR CER levels ,1.6 except for one case with a SUVR CER of 1.76 (Fig. 2) Table 1) .
One of four nondemented p-pre-AD cases (25%) exhibited a positive amyloid PET (Fig. 3A, Table 1 ). In non-AD dementia cases with no or low degrees of AD pathology amyloid PET images were positive in 21.7% (Fig. 3A, Table 1 ) and such cases exhibited Ab phase 3 or 4 (Fig. 3A, Table 1 ).
Binary logistic regression analysis in a model controlled for age, sex, and scan-death interval revealed that positive [ 18 F]flutemetamol amyloid PET uptake patterns identified symptomatic AD cases including those with additional non-AD pathology rather than nondemented p-pre-AD and non-AD controls (P 5 .008; OR: 143.05; 95% CI: 4.681-4371.714). Likewise, symptomatic AD (including those cases with additional non-AD pathology) was distinguished from pure non-AD dementias (P , .002; OR: 155.199; 95% CI: 15.541-1549.928). Differences in the SUVR CER levels confirmed the distinction of AD cases (including cases with fully developed AD pathology and additional non-AD pathology) from non-AD, and non-AD dementia cases ( Fig. 3B ; ANOVA P .001, corrected for multiple testing with Games-Howell post hoc test). Subjects with p-pre-AD (n 5 4) were not distinguished from nondemented control subjects (n 5 3) by [ 18 F]flutemetamol amyloid PET pattern (P 5 1.0, Fisher's exact test) or by SUVR CER differences ( Fig. 3; P 5 .655, ANOVA corrected for multiple testing with Games-Howell post hoc test) in our sample. Similar results have been obtained when using SUVR PONS instead of SUVR CER for statistical analysis (Supplementary Table 1 ).
Discussion
The key novel finding in this study is that [
18 F]flutemetamol amyloid PET detects Ab pathology only in cases with advanced phases of plaque pathology at autopsy, that is, primarily Ab phases 4 and 5 (Fig. 4) . This finding was confirmed by measuring Ab plaque loads as shown in Supplementary Fig. 3 . An additional major finding is that [ 18 F]flutemetamol amyloid PET primarily detects Ab plaque pathology in AD cases with advanced stage Ab pathology representing Ab phases 4 and 5 permitting the distinction between AD and non-AD dementias. In contrast, p-pre-AD cases with Ab phases 1-2 did not exhibit a positive [ 18 F]flutemetamol PET pattern and did not differ in cortex SUVR CER levels from non-AD control cases (Fig. 3 and 4) . Only three of nine Ab phase 3 cases exhibited a positive imaging pattern, and each of these cases was demented. Only one nondemented case with a positive [ 18 F]flutemetamol amyloid PET was observed. However, this case had significant AD pathology with Ab phase 4 and Braak-NFT stage III. As such, given the current rating protocols [ 18 F]flutemetamol amyloid PET analysis allowed a clear cut distinction of .95% of the symptomatic AD subjects with or without additional neurodegenerative pathology from cases free of AD pathology, p-pre-AD cases and cases with non-AD dementias, that is, FTLD, LBD, and vascular dementia. Amyloid PET did not allow a distinction between pure AD cases and AD cases with additional LBD or additional vascular pathology, most likely because both groups exhibited Ab phases 4 or 5. It is well known that amyloid tracers detect plaque pathology in a subgroup of aged nondemented individuals [21] [22] [23] [24] . Our finding that only those nondemented cases with Ab pathology representing advanced phases (i.e., phase 3 and higher) were identified by [ 18 F]flutemetamol amyloid PET points to the interpretation that amyloid PET detects only a subgroup of the p-pre-AD cases: those cases that are close to the threshold of symptomatic AD. Ab plaque load measurements confirmed this interpretation. This finding is in line with the report of amyloid PET-negative cases already showing ADrelated cerebrospinal fluid Ab changes [25] .
Furthermore, amyloid PET with florbetapir (another amyloid tracer) was reported to be positive in cases considered neuropathologically as definite or probable AD, whereas cases categorized as no AD or possible AD with Ab plaque loads up to 1.14% did not exhibit a positive florbetapir PET [9] . Because densitometric measurements of immunoreactivity in general depend on the staining and cutting protocols as well as on correction filters and threshold settings [26] and vary among different laboratories [27] , Ab plaque loads determined here and by Clark et al. [9] cannot be compared directly with one another. Thus, threshold differences of approximately 3%-4% between both studies do not necessarily contradict the comparability of both tracers with PIB as previously published [28] . In this study we, therefore, chose the phases of Ab plaque distribution [11] as a parameter for Ab plaque pathology. This has proven to generate highly reliable and valid information on the amount of Ab plaque pathology as demonstrated in interlaboratory and interrater studies by BrainNet Europe [18, 29] . The increased likelihood of future cognitive decline in amyloid PETpositive nondemented individuals [21] [22] [23] [24] is in agreement with the detection of advanced stage Ab pathology in the nondemented individuals as seen in our autopsy study. 
In vivo [
18 F]flutemetamol binding was reported for amyloid plaques in Tg2576 mice and in AD patients [30] [31] [32] . The fact that cortical Ab plaques and neuritic plaques in Ab phase 1 and 2 cases as well as in 66.7% of the Ab phase 3 cases were not detected by [ 18 F]flutemetamol PET demonstrates that amyloid PET is not sensitive enough to detect initial stages of these pathologies. Only increased numbers of cortical plaques usually associated with increased amounts of cortical soluble and nonplaque-associated insoluble (so called dispersible) Ab aggregates in Ab phase 4 and 5 cases [15, 16] permitted significant [ 18 F]flutemetamol retention in the cortex. The assumption of a threshold for Ab pathology to be passed for detection with amyloid PET is in agreement with the negative PIB amyloid imaging results in aged monkeys with amyloid plaques that may not exhibit sufficient degrees of amyloid pathology (as Ab phase 1-3 cases in this study) to allow detection by amyloid PET methods [33] .
Based on composite SUVR CER of cortical regions [ 18 F] flutemetamol amyloid PET was not sensitive enough for the detection of the hierarchical pattern of Ab plaque expansion in the human brain seen neuropathologically [11] . This finding is in line with that of other authors [34] and highlights the fact that amyloid PET is not as precise as the gold standard of neuropathologic analysis and should be interpreted carefully as only bulk effects will be identified, whereas minor effects may be difficult to detect. Moreover, our finding of no significant increase of cortical composite SUVR CER between Ab phases 0-3 points to interindividual SUVR differences that should not be misinterpreted as early Ab deposition in studies without pathologic confirmation. More detailed studies of pathology and amyloid PET in nondiseased individuals will be required to identify algorithms to distinguish no AD from p-pre-AD cases.
The use of the cerebellum or the pons as reference regions for SUVR calculation and the inclusion of only cortical regions into composite SUVRs preclude the detection of amyloid deposits in these regions characteristic for end-stage AD [11] and explain the failure of current amyloid PET rating strategies in the detections of a hierarchical pattern of Ab deposition. For this purpose, SUVR levels of the brain stem, basal ganglia, and the thalamus would be required as well.
The selection of cerebellum or pons as reference regions, however, appears to be reasonable for amyloid PET given the fact that these two regions are the last to develop Ab plaques in end-stage AD, whereas all other brain regions are affected earlier. Composite SUVR CER and SUVR PONS , thereby, showed similar effects related to the Ab phases (Supplementary Table 1 ).
The neuritic plaque density as determined by the CERAD semiquantitative score confirmed the association of the amyloid PET pattern with the plaque load as described in detail by Curtis et al. [10] . All amyloid PET-positive cases had at least sparse neuritic plaques. [ 18 F]flutemetamol PET did not detect severe abnormal tau pathology in cases with NFT-predominant dementia in line with previously published data for PIB [8] .
One limitation in this study is the variable delay between the last PET scan and death, ranging between 0 and 397 days (mean 104 days; median 78 days), during which AD pathology could have progressed. To minimize the potential error induced by variable scan-death intervals, we included this parameter in the logistic regression model, although our cohort had shorter average scandeath interval compared to a similar study which had a scan-death interval up to 2 years [9] .
Our finding that a distinct subgroup of p-pre-AD cases with very early phases of Ab deposition was not detected by [ 18 F]flutemetamol amyloid PET indicates that p-pre-AD cases can be subdivided into amyloid PET-positive clinically detectable cases and amyloid PET-negative presumably clinically "normal" p-pre-AD cases. The fact that [ 18 F]flutemetamol PET tracer retention was restricted to cases with already advanced stages of Ab pathology (Ab phase 3 and higher) may have an impact on the interpretation and design of clinical studies in amyloid PET-positive nondemented individuals because at this stage the amyloid load is already high.
In summary, by identifying amyloid phase 4 and 5 cases, [ 18 F]flutemetamol PET is well suited to detect amyloid pathology in symptomatic AD and mixed dementia cases with a significant AD component. Nondemented cases with a positive amyloid PET included in this study had advanced Ab pathology at autopsy and, therefore, represent pathologically and clinically diagnosed pre-AD cases. Amyloid PET-negative p-pre-AD cases were related to the very early phases of Ab pathology. However, such amyloid PET-negative p-pre-AD cases do already show initial AD pathology at autopsy.
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